We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System

Published on:
February 2, 2021
Alira Health Secures Breakthrough Device Designation from the FDA on the PEDRA Xauron Perfusion System.

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is proud to announce the firm’s Regulatory Affairs practice has secured a Breakthrough Device Designation from the FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.

“I am very excited and thankful for the opportunity to support a Breakthrough Device Designation with the PEDRA Team. This breakthrough designation will further expedite the premarket approval for an innovative technology that stands to benefit millions of patients suffering from critical limb-threatening ischemia (CLTI),” said Mary McNamara-Cullinane, Senior Vice President, Regulatory Affairs, Alira Health.

PEDRA’s real-time perfusion system is a non-invasive tool used for the treatment of critical limb-threatening ischemia (CLTI), a severe form of peripheral arterial disease (PAD). PAD is defined as a heavy blockage in the arteries of the lower extremities, which reduces blood flow.

FDA’s Breakthrough Device Program creates a pathway for patients to have more timely access to innovative medical devices by expediting their development, assessment, and review while preserving the statutory standards for premarket approval.

About PEDRA Technology, Inc.

PEDRA Technology is a medical device company that focuses on the use of tissue perfusion monitoring in the field of peripheral artery disease (PAD) and critical limb ischemia (CLI). The PEDRA™ Xauron™ Perfusion System is not currently approved for sale in the U.S. Learn more at PEDRAtech.com.

To read the press release on PR Newswire, click here.

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Publications July 14, 2022
How to successfully use the EMA IRIS portal to ensure timely submissions
Submitting your scientific advice (SA), orphan drug designation (ODD) or Innovation Task Force (ITF) consultation to the EMA? Avoid delays with our submission recommendations.
European Medicines Agency Orphan Drug Regulatory
Multimedia July 12, 2022
Webinar Replay: What You Should Know About MDR Best Practices, Including PMCF
Discover the major changes introduced by the MDR, including the post-market requirements, and especially the Post-Market Clinical Follow-up (PMCF).
MedTech Regulatory
Events June 30, 2022
DTx France 2022
We are pleased to announce that we will be joining as speakers and exhibitors at DTx France 2022. This hybrid event will focus on the latest DTx trends, regulatory framework, market(...)
DTx trends Market Access Regulatory
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.